3 enrolling by invitation. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Enrolling by invitation 3 |
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. PLB1004, Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab - Non-Small-Cell Lung Cancer | Phase 3 | Enrolling by invitation | Avistone Biotechnology Co., Ltd. | 327 | 2023-12-01 | 2026-04-23 |
| Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection Almonertinib, Pemetrexed, Cisplatin - Non-small Cell Lung Carcinoma | Phase 3 | Enrolling by invitation | Chinese Academy of Medical Sciences | 606 | 2021-08-01 | 2022-02-24 |
| FHND9041 Versus Afatinib for Non-small Cell Lung Cancer FHND9041, Afatinib - Non Small Cell Lung Cancer | Phase 3 | Enrolling by invitation | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 350 | 2021-08-01 | 2025-01-06 |
Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (1)
Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Lung Neoplasms (2)
Afatinib (1) · Cisplatin (1) · Pemetrexed (1) · aumolertinib (1)
Avistone Biotechnology Co., Ltd. (1) · Chinese Academy of Medical Sciences (1) · Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (1)
China (3)
Yuankai Shi (1)